In this episode, I speak with neurologist and researcher Professor Barbara Willekens about one of the most exciting and complex developments in MS research: CAR-T cell therapy.

Originally developed for blood cancers, this innovative treatment is now being explored for autoimmune diseases like multiple sclerosis. We discuss how CAR-T therapy works, how it differs from existing MS treatments, and why it may have the potential to "reset" the immune system.

At the same time, we take a close look at the current scientific evidence, including early clinical data, safety concerns, and why this therapy is still far from routine clinical use. You'll also learn who might be eligible for current trials and what the future of CAR-T in MS care could look like.

You can read the full blog article here: https://ms-perspektive.de/EN/163-car-t-cell-therapy

🧠 What you'll learn in this episode

• What CAR-T cell therapy is and how it works
• Why B cells play a key role in MS
• How CAR-T differs from current MS treatments
• What "immune reset" means—and why it's still a hypothesis
• Who might be eligible for CAR-T therapy trials
• Risks such as cytokine release syndrome and neurotoxicity
• What we can learn from lupus and cancer research
• Where clinical trials are currently taking place
• Why experts are both hopeful and cautious

🔬 Resources & Links

• Previous episode: MS Brain Health Strategy (Episode 125)
• Clinical trials database: https://clinicaltrials.gov
• Mackensen et al., Nature Medicine (2022) – CAR-T in lupus
• DiLillo et al., Blood Advances (2021)

Note: This episode is for informational purposes only and does not replace medical advice. Please consult your healthcare provider before making any treatment decisions.

---

See you soon and try to make the best out of your life,
Nele

For more information and positive thoughts, subscribe to my newsletter for free.

Click here for an overview of all podcast episodes published so far.